CN116355905A - 一种促进小rna病毒科病毒复制的bhk-21细胞系、构建方法及应用 - Google Patents
一种促进小rna病毒科病毒复制的bhk-21细胞系、构建方法及应用 Download PDFInfo
- Publication number
- CN116355905A CN116355905A CN202310323610.4A CN202310323610A CN116355905A CN 116355905 A CN116355905 A CN 116355905A CN 202310323610 A CN202310323610 A CN 202310323610A CN 116355905 A CN116355905 A CN 116355905A
- Authority
- CN
- China
- Prior art keywords
- klhl34
- gene
- sgrna
- bhk
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000709664 Picornaviridae Species 0.000 title claims abstract description 22
- 238000010276 construction Methods 0.000 title claims abstract description 10
- 230000010076 replication Effects 0.000 title abstract description 15
- 230000001737 promoting effect Effects 0.000 title abstract description 5
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 43
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims abstract description 42
- 230000008685 targeting Effects 0.000 claims abstract description 21
- 229960005486 vaccine Drugs 0.000 claims abstract description 17
- 101000945191 Homo sapiens Kelch-like protein 34 Proteins 0.000 claims abstract description 16
- 102100033581 Kelch-like protein 34 Human genes 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 101150002907 KLHL34 gene Proteins 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 108091033409 CRISPR Proteins 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 238000003209 gene knockout Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 13
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 238000000137 annealing Methods 0.000 claims description 10
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 238000010354 CRISPR gene editing Methods 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 229950010131 puromycin Drugs 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 238000003113 dilution method Methods 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 10
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 abstract description 7
- 239000000427 antigen Substances 0.000 abstract description 7
- 102000036639 antigens Human genes 0.000 abstract description 7
- 108091007433 antigens Proteins 0.000 abstract description 7
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 110
- 238000003776 cleavage reaction Methods 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 231100000221 frame shift mutation induction Toxicity 0.000 description 4
- 230000037433 frameshift Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101710197658 Capsid protein VP1 Proteins 0.000 description 3
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000012224 gene deletion Methods 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102000008836 BTB/POZ domains Human genes 0.000 description 2
- 108050000749 BTB/POZ domains Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000001728 clone cell Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000710194 Foot-and-mouth disease virus - type O Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 1
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000222712 Kinetoplastida Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061661 Orchis Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000010357 RNA editing Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 102100020926 Thialysine N-epsilon-acetyltransferase Human genes 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32151—Methods of production or purification of viral material
- C12N2770/32152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明属于基因工程领域,具体涉及一种促进小RNA病毒科病毒复制的BHK‑21细胞系、构建方法及应用。本发明提供了一种特异性靶向KLHL34的sgRNA,所述sgRNA能够特异性靶向KLHL34基因,结合CRISPR‑Cas9技术在BHK‑21细胞系中实现了KLHL34基因的敲除,获得的单克隆细胞系能够显著促进小RNA病毒科病毒FMDV的复制,提高FMDV疫苗的生产量和抗原产量,可作为小核糖核酸病毒科病毒疫苗尤其是FMDV疫苗的生产细胞系,具有广阔的应用前景。
Description
技术领域
本发明属于基因工程领域,具体涉及一种促进小RNA病毒科病毒复制的BHK-21细胞系、构建方法及应用。
背景技术
小核糖核酸(RNA)病毒科(Picomaviridae)是由RNA病毒中最小的类群组成的一科,主要包括肠道病毒属、鼻病毒属、心病毒属以及口疮病毒属等。口蹄疫(foot-and-mouthdis ease,FMD)是由口蹄疫病毒(foot-and-mouth disease virus,FMDV)引起的急性、热性、高度接触性传染的动物疫病,严重危害猪、牛、羊等偶蹄类动物。FMDV是单股正链RNA病毒,属于小RNA病毒科口蹄疫病毒属,有O、A、C、SAT1、SAT2、SAT3和Asia1 7个血清型,且各型之间没有交叉免疫保护,即使同一血清型不同毒株抗原之间交叉免疫保护也存在差异。因其基因组为单股正链RNA,具有很高的变异性,易产生新毒株,导致疫苗不能完全覆盖田间流行毒株,这就给口蹄疫的免疫防控带来巨大挑战。开发高效疫苗是当前防控该病最有效的举措,而选取病毒高效繁殖的细胞系是制备高效疫苗的前提,急需开展相关工作。
CRISPR-Cas9是细菌和古细菌在长期演化过程中形成的一种适应性免疫防御系统,可用来对抗入侵的病毒及外源DNA。基于原核生物的适应性免疫防御系统研发出了CRISPR-Cas9基因编辑技术,该技术就是通过人工设计的sgRNA来识别目的基因组序列,并引导Cas9蛋白酶进行有效切割DNA双链,形成双链断裂。通常情况下,细胞会采用非同源末端连接(Non-homologous end joining,NHEJ)或同源重组修复(Homology-directedrepair,HDR)途径来对造成的断裂进行修复,实现基因的敲除与修饰。前者在修复过程中通常会发生碱基插入或缺失的错配现象,造成移码突变,使靶标基因失去功能,从而实现特定基因的敲除。
KLHL34是Kelch样(KLHL)基因家族的一员,它编码一组具有BTB/POZ结构域、BAC K结构域和5-6个Kelch基序的蛋白质。Perez-Torrado等人论述了BTB/POZ结构域促进与其他蛋白质的结合,其功能涉及多种细胞内分子机制,包括细胞骨架组织的控制、离子通道的选择等,某些KLHL基因的突变会导致孟德尔疾病或人类癌症。
本发明首先提供了一种特异性靶向KLHL34基因的sgRNA,所述的sgRNA能够特异性靶向KLHL34基因,结合CRISPR-Cas9技术在BHK-21细胞中实现了KLHL34基因的敲除,获得的KLHL34基因敲除单克隆细胞系BHK-21-KLHL34-KO能够显著促进小RNA病毒FMD V的复制,提高小RNA病毒疫苗的生产量和抗原产量,可作为小RNA病毒疫苗的生产细胞系,具有广阔的应用前景。
发明内容
针对上述问题,本发明首先提供了一种特异性靶向KLHL34基因的sgRNA,所述的sgR NA能够特异性靶向KLHL34基因,结合CRISPR-Cas9技术在BHK-21细胞中实现了KLHL34基因的敲除,获得的KLHL34基因敲除单克隆细胞系BHK-21-KLHL34-KO能够显著促进小RNA病毒FMDV的复制,提高小RNA病毒疫苗的生产量和抗原产量,可作为小RNA病毒疫苗的生产细胞系。具体包括以下内容:
第一方面,本发明提供了一种特异性靶向KLHL34基因的sgRNA,所述sgRNA包括sgRNA-1和/或sgRNA-2;
所述sgRNA1的靶向序列为:TGGTCACGCGGGTGCCGTTG;
所述sgRNA2的靶向序列为:GGTGCCAACCCGTAACGTAG。
优选地,所述sgRNA1是由sgRNA1-F和sgRNA1-R退火形成的双链片段;所述sgRNA 2是由sgRNA2-F和sgRNA2-R退火形成的双链片段;
sgRNA1-F:5’-CACCGTGGTCACGCGGGTGCCGTTG-3’;
sgRNA1-R:5’-AAACCAACGGCACCCGCGTGACCAC-3’;
sgRNA2-F:5’-CACCGGGTGCCAACCCGTAACGTAG-3’;
sgRNA2-R:5’-AAACCTACGTTACGGGTTGGCACCC-3’。
第二方面,本发明提供了上述第一方面所述的sgRNA在敲除KLHL34基因或在制备KL HL34基因敲除细胞系中的应用。
第三方面,本发明提供了一种用于敲除KLHL34基因的试剂或试剂盒,所述试剂或试剂盒包括上述第一方面所述的sgRNA,或靶向敲除KLHL34基因的打靶载体;所述靶向敲除K LHL34基因的打靶载体包括上述第一方面所述的sgRNA和Cas9蛋白基因的编码序列。
第四方面,本发明提供了一种KLHL34基因编码蛋白功能丧失细胞系的构建方法,所述方法为:利用CRISPR/Cas9系统,使用上述第一方面所述的sgRNA敲除所述细胞系中的KL HL34基因。
第五方面,本发明提供了一种KLHL34基因敲除BHK-21细胞系的构建方法,所述方法为:利用CRISPR/Cas9系统,使用上述第一方面所述的sgRNA敲除所述BHK-21细胞系中的KLHL34基因。
优选地,所述方法包括以下步骤:
(1)制备上述第一方面所述的特异性靶向KLHL34基因的sgRNA;
(2)将步骤(1)制备的sgRNA退火并连接至PX459质粒,得到同时表达Cas9蛋白基因和打靶sgRNA序列的重组质粒;
(3)将步骤(2)制备的重组质粒转染BHK-21细胞,用嘌呤霉素(puromycin)抗生素筛选和细胞有限稀释法获得KLHL34基因功能缺失的BHK-21细胞系。
第六方面,本发明提供了一种上述第五方面所述方法构建获得的KLHL34基因敲除BHK-21细胞系。
第七方面,本发明提供了上述第六方面所述的KLHL34基因敲除BHK-21细胞系作为小RNA病毒科病毒或病毒疫苗生产细胞系的应用。
优选地,所述小RNA病毒科病毒为口蹄疫病毒。
本发明的有益效果是:①本发明提供了一种靶向KLHL34基因的sgRNA,所述sgRNA能够特异性靶向KLHL34基因,结合CRISPR-Cas9技术可实现BHK-21细胞中KLHL34基因的敲除,打靶准确、敲除效率高;②本发明提供了一种通过CRISPR-Cas9技术将所述sgRN A转染于BHK-21细胞,构建KLHL34基因编码蛋白功能丧失BHK-21细胞系的方法;③依据本发明所述方法获得的单克隆细胞系BHK-21-KLHL34-KO能够显著促进小RNA病毒科病毒FMDV的复制,提高小RNA病毒科病毒FMDV疫苗的生产量和抗原产量,可作为小核糖核酸病毒科病毒或病毒疫苗的生产细胞系,具有广阔的应用前景。
附图说明
图1靶向KLHL34基因组区域的sgRNA示意图;
图2BHK-21-KLHL34-KO-1细胞系基因缺失突变型分析图;
图3BHK-21-KLHL34-KO-2细胞系基因缺失突变型分析图;
图4Western Blot检测敲除细胞系BHK-21-KLHL34-KOs中KLHL34基因的蛋白水平结果;
图5KLHL34基因功能缺失细胞系BHK-21-KLHL34-KOs细胞活力检测结果;
图6相对定量检测FMDV感染BHK-21-KLHL34-WT和BHK-21-KLHL34-KOs不同时间的mRNA水平差异;
图7Western blot检测FMDV在BHK-21-KLHL34-WT和BHK-21-KLHL34-KOs细胞中的蛋白水平差异;
图8FMDV在BHK-21-KLHL34-KOs细胞中增殖后的病毒滴度检测结果。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合附图对本发明的各实施例进行详细的阐述。然而,本领域的普通技术人员可以理解,在本发明各实施例中,为了使读者更好地理解本申请而提出了许多技术细节。但是,即使没有这些技术细节和基于以下各实施例的种种变化和修改,也可以实现本申请所要求保护的技术方案。
定义
术语“蛋白功能丧失”是指通过对编码蛋白的基因进行敲除、突变或在编码蛋白的基因片段中插入部分基因,使得基因编码蛋白发生移码突变,导致基因编码蛋白的功能丧失。本发明通过对宿主细胞中的KLHL34基因靶向敲除,导致KLHL34基因编码蛋白的功能丧失,进而构建了KLHL34基因编码蛋白功能丧失的BHK-21细胞系,并用于FMDV的增殖。但是本发明并不局限于KLHL34基因敲除,也可通过其他技术手段使宿主细胞BHK-21中KLHL34基因编码蛋白的功能丧失,并用于构建KLHL34基因编码蛋白功能丧失的细胞系。
术语“基因打靶”是指利用DNA定点同源重组进行细胞或生物个体遗传信息定向改变的定向转基因技术,主要包括基因敲除、基因灭活、基因敲入、点突变、缺失突变以及染色体组大片段删除等。其中“基因敲除”是指通过一定的途径使特定靶基因失活或缺失。本发明通过基因敲除技术,使宿主细胞BHK-21中的KLHL34因敲除,获得的KLHL34基因编码蛋白功能丧失的单克隆细胞系能促进FMDV的增殖;本发明也可以通过对宿主细胞BHK-21中的KLHL34基因突变,或插入基因片段,导致KLHL34基因编码蛋白发生移码突变,成功构建出KLHL34基因编码蛋白功能丧失的单克隆细胞系。
术语“sgRNA”为向导RNA,是指在RNA编辑的过程中引导尿苷残基插入或缺失到动质体(kinetoplastid)中,属于一种小型非编码RNA。
本发明通过人工合成了靶向KLHL34基因的sgRNA;本发明在直接靶向剪接KLHL34基因的基础上,利用CRISPR/Cas9联合特异性敲除KLHL34基因的方法,以宿主细胞BHK-21细胞为例,进行了KLHL34基因(KLHL34氨基酸序列如SEQ ID NO.1所示;CDS序列如S EQ IDNO.2所示)敲除,为FMDV疫苗的生产提效提供了一种策略。本发明虽然仅对宿主细胞BHK-21中KLHL34基因进行敲除,获得了一种基因敲除宿主细胞,但是本发明所述的方法可以推论并扩展到对其他动物细胞中KLHL34基因敲除,构建具有提升FMDV抗原产量的基因敲除细胞系。
CRISPR/Cas9系统对基因的定向识别和剪切是由sgRNA和Cas9实现的,sgRNA决定了Cas9的靶向性,也决定了Cas9的切割活性。本发明旨在应用CRISPR/Cas9基因编辑技术,通过体内外筛选针对KLHL34基因的sgRNA序列,实现KLHL34基因的准确、高效地敲除,获得一种能够促进FMDV抗原产量的KLHL34基因敲除单克隆细胞系,从而为FMDV疫苗的生产提供新的策略。
利用CRISPR/Cas9基因编辑技术,通过靶向KLHL34基因的sgRNA引导Cas9蛋白结合到KLHL34基因特定序列位置对DNA双链进行切割,造成基因双链断裂,在细胞自身修复机制作用下,产生随机突变,核苷酸的缺失或插入等突变会造成基因的读码框发生改变,最终达到基因编码蛋白功能丧失的目的,获得基因编码蛋白功能丧失细胞系。
下述实施例中的实验方法,如无特殊说明,均为常规方法;下述实施例中所用的试验材料,如无特殊说明,均为自常规生化试剂公司购买获得。
以下实施例中所涉及的材料:O/BY/CHA/2010来源于中国农业科学院兰州兽医研究所国家口蹄疫参考实验室;BHK-21细胞由本实验室提供,细胞培养使用含有10%胎牛血清和1%双抗的MEM培养基进行培养;PX459载体由中国农业大学吴森教授惠赠。
大肠杆菌Trans5α感受态、T4 DNA连接酶、TB GreenⅡ购自宝生物工程(大连)有限公司;限制性核酸内切酶BbsI购自NEB公司;质粒提取试剂盒、Trizol试剂和蛋白预染Marker购自Invitrogen公司;胶回收试剂盒、微量DNA提取试剂盒购自OMEGA公司;MEM细胞培养基及0.25% EDTA胰酶购自Gibco公司;胎牛血清(FBS)购自Biological Industries(BI)公司;Polyplus jetPRIME转染试剂购自Polyplus Transfection公司;Western-抗体稀释液购自碧云天生物技术有限公司;10×PCR Buffer购自康为世纪生物科技有限公司;兔抗KLHL34多克隆抗体、鼠抗β-Actin多克隆抗体购自proteintech公司;辣根过氧化物酶(HRP)标记的山羊抗兔IgG抗体、HRP标记的山羊抗鼠IgG抗体购自Sigma-Aldrich(USA)公司;O型FMDV VP1单克隆抗体由本实验室制备保存。
以下实施例所述的KLHL34基因CDS序列如SEQ ID NO.2所示,氨基酸序列如SEQ IDNO.1所示。
实施例1KLHL34基因敲除BHK-21细胞系的构建
1.KLHL34-sgRNA重组质粒构建
sgRNA靶点的设计:在NCBI中查询鼠源KLHL34基因序列,基于张峰实验室网站http://crispr.mit.edu/设计sgRAN,在KLHL34的第1个外显子区域的1995位置和2361位置分别设计两条sgRNA序列sgRNA1和sgRNA2:
所述sgRNA1的靶向序列为:TGGTCACGCGGGTGCCGTTG(SEQ ID NO.3所示);所述sgRNA1是由sgRNA1-F(5’-CACCGTGGTCACGCGGGTGCCGTTG-3’,SEQ ID NO.5所示)和sgRNA1-R(5’-AAACCAACGGCACCCGCGTGACCAC-3’,SEQ ID NO.6所示)退火形成的双链片段;
所述sgRNA2的靶向序列为:GGTGCCAACCCGTAACGTAG(SEQ ID NO.4所示);所述sgRNA2是由sgRNA2-F(5’-CACCGGGTGCCAACCCGTAACGTAG-3’,SEQ ID NO.7所示)和sgRNA2-R(5’-AAACCTACGTTACGGGTTGGCACCC-3’,SEQ ID NO.8所示)退火形成的双链片段。
sgRNA的退火杂交:将sgRNA上、下游序列合成产物稀释至100μmol/L后,取上、下游引物各22.5μL,并加入10×PCR buffer,共50μL体系按照99℃退火处理5min,使上下游引物形成双链;
PX459载体的酶切:利用限制性内切酶BbsI酶切PX459载体,按照10×buffer 2μL、P X459载体5μL,BbsI 1μL、ddH2O 12μL,共20μL反应体系,37℃酶切4h,胶回收酶切产物;
酶切载体与sgRNA的连接:配制10μL连接反应体系,其中,10×T4连接酶buffer 1μL、PX459酶切片段2μL、退火后的sgRNA 6μL,T4连接酶1μL,置16℃连接2h;
PX459-sgRNA连接产物转化:将连接产物转化Trans5α感受态细胞,涂布于含Amp的L B固体培养皿上,37℃过夜培养,挑取菌落振荡培养后,提取质粒,测序。使用MegAlign软件对测序结果与目的基因序列进行对比,成功构建具有靶向KLHL34基因不同外显子的sgRNA重组质粒,位置和序列信息如图1;重组质粒分别命名为:PX459-KLHL34-sgRNA-1、PX459-KLHL34-sgRNA-2。
2.细胞的转染与筛选
按照jetPRIME转染试剂操作步骤,将2μg PX459-KLHL34-sgRNA重组质粒转染培养于6孔板的BHK-21细胞中,将细胞培养板置于37℃、5% CO2培养箱中培养24h。
为了剔除大量sgRNA阴性细胞,转染24h后,用含终浓度3μg/mL的嘌呤霉素将细胞消化传代,置于37℃、5% CO2培养箱中培养加压筛选3天,更换新鲜培养基使阳性细胞正常生长。消化经加压筛选的细胞并计数,然后用MEM完全培养基将细胞稀释至10个细胞/mL,将稀释后的细胞悬液加入96孔板中,0.1mL/孔,即每孔中有1个细胞。将细胞培养板置含5%CO2的37℃培养箱中培养5-7d后观察,剔除双克隆、多克隆细胞孔,标记单克隆且细胞状态良好的细胞孔,传代至48孔板中继续培养,待细胞长满后依次传代至12孔板、6孔板中进行扩大培养。
3.单克隆细胞株的测序鉴定
取野生型细胞与各个待鉴定单克隆细胞株,按照细胞微量DNA提取试剂盒说明书分别提取DNA,用KLHL34鉴定引物(check-F:5’-CCAGACCCGCATCTTGCTGATT-3’(SEQ ID NO.9所示),check-R:5’-CCCACCTTCCTCCAGCTGCAGC-3’(SEQ ID NO.10所示))扩增含有sgRNA靶向位点的片段,经1%琼脂糖凝胶电泳后,胶回收扩增产物,测序。将待鉴定单克隆细胞株与野生型细胞株扩增产物的测序结果进行序列分析,将显示因碱基插入或碱基缺失而导致基因序列产生移码突变的对应细胞株以及序列比对没有发生碱基改变的细胞株,分别标记为BHK-21-KLHL34-KO和BHK-21-KLHL34-WT。
对测序结果与目的基因序列进行比对分析,结果如图2和3所示,BHK-21-KLHL34-KO 1在Cas9外显子1的1995预定切割位置处(距离PAM基序(GGG)第4和5个碱基之间切割)有1个碱基的缺失;BHK-21-KLHL34-KO2在外显子1的2361预定切割位置处(距离P AM基序(TGG)第4和5个碱基之间切割)有7个碱基的缺失。
4.Western blot分析
蛋白水平鉴定时用KLHL34的抗体(Cat No.21981-1-AP),利用Western blot检测KLH L34的蛋白水平表达。结果如图4所示,BHK-21-KLHL34-KO1和BHK-21-KLHL34-KO2细胞系中均检测不到KLHL34的蛋白表达。上述结果表明,KLHL34基因敲除BHK-21细胞系构建成功,分别命名为BHK-21-KLHL34-KO1和BHK-21-KLHL34-KO2。
实施例2KLHL34基因敲除BHK-21细胞系的活力检测
分别将野生型和KLHL34基因敲除细胞消化,调整细胞悬液密度为1-2×105个细胞/mL,接种于96孔细胞培养板中,100μL/孔,置37℃、5% CO2细胞培养箱中培养5h;向每孔加入10μL CCK-8溶液,继续将培养板放入培养箱中孵育3h,用酶标仪测定其在450nm的吸光度,分析数据。
结果如图5所示,KLHL34基因敲除BHK-21细胞系BHK-21-KLHL34-KO1和BHK-21-KLHL34-KO2与正常型BHK-21细胞的细胞活力相同,表明KLHL34基因的敲除并不影响宿主细胞的正常生长。
实施例3FMDV在BHK-21-KLHL34-KOs细胞系中的复制
1.细胞接毒感染
取成功构建的KLHL34敲除的BHK-21细胞系(BHK-21-KLHL34-KO1、BHK-21-KLHL34-KO2)及对照细胞系(转染PX459空载质粒的BHK-21细胞系,BHK-21-KLHL34-WT)在35mm的细胞培养皿中培养到大约80%的汇合度时,弃掉培养基,加入1mL PBS清洗细胞两次后,按MOI=0.1的口蹄疫病毒O/BY/CHA/2010,在培养箱中孵育1h;吸掉病毒液,加入1mL PBS清洗细胞两次后,加入2mL MEM培养基。置细胞培养箱中培养,然后分别在感染后不同时间收集样品,用RT-qPCR、Western blot、TCID50等不同方法综合评价口蹄疫病毒的复制情况。
2.实时荧光定量检测病毒复制水平
取FMDV接毒后不同时间点收取的细胞,按照Trizol裂解法说明书提取总RNA,测定浓度后,利用反转录试剂盒进行反转录获得cDNA。采用Mx3005P-QPCR系统(Agilent Technologies,USA)和TB GreenⅡPremix Ex Taq 10μL,上、下游引物(FMDV-3D-F:CACTGGTGACAGGCTAAGG,SEQ ID NO.11所示;FMDV-3D-R:CCCTTCTCAGATTCCG AGT,SEQ IDNO.12所示;)各0.5μL,cDNA1μL,ddH2O 8μL,共20μL的体系配置预混反应,并按照95℃2min;95℃10s,60℃30s(收集荧光),共40个循环进行荧光定量PCR反应,利用GAPDH作为内参基因,对FMDV的mRNA水平进行定量,所有试验设置三个重复,用2-△△CT方法分析数据。
结果如图6所示,感染FMDV后的不同时间点,BHK-21-KLHL34-KO细胞中FMDV的mRNA水平均显著高于对照细胞BHK-21-KLHL34-WT,说明KLHL34基因功能缺失单克隆细胞系BHK-21-KLHL34-KOs能够显著促进FMDV的复制。
3.Western blot分析病毒蛋白的表达
培养在35mm细胞培养皿中的BHK-21-KLHL34-KO和BHK-21-KLHL34-WT细胞,按照上述方法进行病毒感染,于病变后收集细胞样品,收集的细胞样品中加入200μL细胞裂解液(Pierce),待细胞充分裂解之后离心除去细胞碎片收集上清液,用BCA蛋白定量试剂盒(Thermo)定量总蛋白。剩余部分加入四分之一体积的4×上样缓冲液混匀,煮沸5min,室温静置冷却。利用定量结果确定上样体积,上样量一般为20-40μg。蛋白样品经SDS-PAGE电泳后转NC膜,冰浴中100V恒压转膜1.5h。5%脱脂奶粉封闭1h。以兔抗KLHL34抗体、FMD V VP1单抗和鼠抗β-Actin抗体作为一抗,4℃孵育过夜。HRP标记的相应二抗室温孵育1h。蛋白检测用Thermo公司的显色试剂盒(PierceTM ECL Western Blotting Substrate),图片经I mageLab 4.1(BIO-RAD)扫描成像。
结果如图7显示,感染FMDV后,BHK-21-KLHL34-KO细胞中口蹄疫病毒结构蛋白VP 1的丰度明显高于对照BHK-21-KLHL34-WT细胞中的蛋白丰度。说明KLHL34基因功能缺失单克隆细胞系BHK-21-KLHL34-KOs能够显著促进FMDV的复制。
4.病毒滴度TCID50测定
将FMDV分别感染BHK-21-KLHL34-KO和BHK-21-KLHL34-WT细胞,不同时间点收取病毒液,反复冻融三次后,离心取上清,用无血清的MEM培养基将待测样品进行10倍倍比稀释,用各稀释度毒液分别接种长满单层BHK-21细胞的96孔培养板中,每个稀释度接种8个孔,100μL/孔。置于37℃、5%CO2细胞培养箱中培养3天,期间观察并记录细胞病变(C PE)情况,根据Reed-Muench法计算TCID50并分析。
结果如图8所示,BHK-21-KLHL34-KO细胞不同时间点的感染样品,病毒滴度均显著高于对照野生型细胞,说明敲除KLHL34之后能够显著促进FMDV复制。
以上结果表明,KLHL34基因敲除BHK-21细胞系能够显著促进小核糖核酸病毒科病毒F MDV的复制,促进小核糖核酸病毒科病毒的复制,可用于小核糖核酸病毒科病毒疫苗的生产。
Claims (10)
1.一种特异性靶向KLHL34基因的sgRNA,其特征在于,所述sgRNA包括sgRNA-1和/或sgRNA-2;
所述sgRNA1的靶向序列为:TGGTCACGCGGGTGCCGTTG;
所述sgRNA2的靶向序列为:GGTGCCAACCCGTAACGTAG。
2.如权利要求1所述的sgRNA,其特征在于,所述sgRNA1是由sgRNA1-F和sgRNA1-R退火形成的双链片段;所述sgRNA2是由sgRNA2-F和sgRNA2-R退火形成的双链片段;
sgRNA1-F:5’-CACCGTGGTCACGCGGGTGCCGTTG-3’;
sgRNA1-R:5’-AAACCAACGGCACCCGCGTGACCAC-3’;
sgRNA2-F:5’-CACCGGGTGCCAACCCGTAACGTAG-3’;
sgRNA2-R:5’-AAACCTACGTTACGGGTTGGCACCC-3’。
3.如权利要求1或2所述的sgRNA在敲除KLHL34基因或在制备KLHL34基因敲除细胞系中的应用。
4.一种用于敲除KLHL34基因的试剂或试剂盒,其特征在于,所述试剂或试剂盒包括权利要求1或2所述的sgRNA,或靶向敲除KLHL34基因的打靶载体;所述靶向敲除KLHL34基因的打靶载体包括权利要求1或2所述的sgRNA和Cas9蛋白基因的编码序列。
5.一种KLHL34基因编码蛋白功能丧失细胞系的构建方法,其特征在于,所述方法为:利用CRISPR/Cas9系统,使用权利要求1或2所述的sgRNA敲除所述细胞系中的KLHL34基因。
6.一种KLHL34基因敲除BHK-21细胞系的构建方法,其特征在于,所述方法为:利用CRISPR/Cas9系统,使用权利要求1或2所述的sgRNA敲除所述BHK-21细胞系中的KLHL34基因。
7.如权利要求6所述的方法,其特征在于,所述方法包括以下步骤:
(1)制备权利要求1或2所述的特异性靶向KLHL34基因的sgRNA;
(2)将步骤(1)制备的sgRNA退火并连接至PX459质粒,得到同时表达Cas9蛋白基因和打靶sgRNA序列的重组质粒;
(3)将步骤(2)制备的重组质粒转染BHK-21细胞,用嘌呤霉素(puromycin)抗生素筛选和细胞有限稀释法获得KLHL34基因功能缺失的BHK-21细胞系。
8.如权利要求6或7所述方法构建获得的KLHL34基因敲除BHK-21细胞系。
9.如权利要求8所述的KLHL34基因敲除BHK-21细胞系作为小RNA病毒科病毒或病毒疫苗生产细胞系的应用。
10.如权利要求9所述的应用,其特征在于,所述小RNA病毒科病毒为口蹄疫病毒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310323610.4A CN116355905A (zh) | 2023-03-29 | 2023-03-29 | 一种促进小rna病毒科病毒复制的bhk-21细胞系、构建方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310323610.4A CN116355905A (zh) | 2023-03-29 | 2023-03-29 | 一种促进小rna病毒科病毒复制的bhk-21细胞系、构建方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116355905A true CN116355905A (zh) | 2023-06-30 |
Family
ID=86914550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310323610.4A Pending CN116355905A (zh) | 2023-03-29 | 2023-03-29 | 一种促进小rna病毒科病毒复制的bhk-21细胞系、构建方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116355905A (zh) |
-
2023
- 2023-03-29 CN CN202310323610.4A patent/CN116355905A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107828738A (zh) | 一种dna甲基转移酶缺陷型cho细胞系及其制备方法及应用 | |
CN107502608A (zh) | 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用 | |
CN111849979B (zh) | 一种靶向敲除RPSA基因的sgRNA及RPSA基因敲除细胞系的构建方法 | |
CN112980878B (zh) | Hdac8基因敲除的bhk-21细胞系及其构建方法和应用 | |
CN111549059A (zh) | Tpl2基因敲除hek293t细胞系及其构建方法和应用 | |
WO2023174305A1 (zh) | Rna靶向基因编辑工具的开发 | |
CN110885823B (zh) | 一种长链非编码RNA猪Lnc-000649及其应用 | |
CN109182562A (zh) | 与蛋鸭卵泡发育相关的miRNA apla-mir-25-42及其检测引物、抑制物和应用 | |
CN108611351A (zh) | ID1基因的sgRNA、ID1基因的敲除方法、BHK-21细胞系及其用途 | |
CN113862226B (zh) | 一种Dicer基因敲除的BHK-21细胞系 | |
CN111808858B (zh) | 一种siRNA序列及其靶标在提高PEDV毒价中的应用 | |
CN112852874A (zh) | Hdac5基因敲除的bhk-21细胞系及其构建方法和应用 | |
CN112852745A (zh) | Hdac3基因敲除的bhk-21细胞系及其构建方法和应用 | |
CN116355905A (zh) | 一种促进小rna病毒科病毒复制的bhk-21细胞系、构建方法及应用 | |
CN116445486B (zh) | Klhl34敲除细胞系的构建及作为小rna病毒科病毒生产细胞系的应用 | |
CN108324727B (zh) | miR-1307或其前体在制备预防和/或治疗口蹄疫病毒感染的组合物中的应用 | |
CN112877275B (zh) | Hdac2基因敲除的bhk-21细胞系及其构建方法和应用 | |
CN112094854B (zh) | 一种检测中华鳖黄病毒的特异性引物、探针及试剂盒 | |
CN110904056B (zh) | 一种传染性支气管炎病毒rH120-YZS1Δ5a及其构建方法和应用 | |
CN102703506A (zh) | α1,2-岩藻糖转移酶基因沉默的体细胞克隆猪及其生产方法与应用 | |
CN112574995B (zh) | 用于马立克病病毒LAT基因簇miRNA基因编辑的gRNA引物及其应用 | |
CN117417895A (zh) | Atg16l1或其wd40结构域敲除细胞系作为小rna病毒科病毒生产细胞系的应用 | |
CN115896035B (zh) | 一种应用于病毒扩增的Vero细胞株、其构建方法及应用 | |
CN111454944B (zh) | 一种分离的rna及其dna模板的合成方法 | |
CN115948466A (zh) | Tollip敲除细胞系的构建及作为小RNA病毒科病毒疫苗生产细胞系的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |